---
title: "Financials | Lionheart Longevity Investor Relations"
description: "Lionheart Health selected financial information, 2022 to present, and annual reports."
url: https://investors.lionheartlongevity.com/financials
---

Financials

# Financial Information

Selected financial information from launch in 2022 to the present, and the company’s annual reports.

Unaudited · Prior to CPA review

## Selected Financial Information

Amounts in U.S. dollars; losses in parentheses. Updated October 26, 2026.

| Financial metric                                     | 2022 launch period | FY 2023    | FY 2024    | FY 2025    | 2026 YTD through Oct. 23 |
| ---------------------------------------------------- | ------------------ | ---------- | ---------- | ---------- | ------------------------ |
| Sales / service revenue                              | $0                 | $24,569    | $77,840    | $117,068¹  | $176,619²                |
| Cost of goods sold                                   | $0                 | $0         | $47,511    | $24,034    | Pending²                 |
| Identified Lionheart 240 Stimulus factory COGS       | —                  | —          | —          | —          | $12,800⁶                 |
| Other product COGS, freight and duties               | —                  | —          | —          | —          | Pending reconciliation   |
| Gross profit                                         | $0                 | $24,569    | $30,330    | $93,034    | Pending²                 |
| Total reported expenses, excluding COGS³             | $59,058⁵           | $668,812   | $995,881   | $392,117   | Pending reconciliation   |
| Executive non-cash compensation expense estimate     | —                  | —          | —          | —          | $495,215⁷                |
| Other income                                         | $0                 | $0         | $0         | $253,782⁴  | Pending                  |
| Net income / (loss)                                  | ($59,058)⁵         | ($644,243) | ($965,551) | ($45,301)¹ | Pending²                 |
| Product / device cash purchases for R&D              | $24,448⁵           | —          | —          | —          | —                        |
| Provisional cash-basis result                        | ($59,058)⁵         | —          | —          | —          | —                        |
| Full-year 2026 sales forecast, separate from actuals | —                  | —          | —          | —          | Pending confirmation     |

### 2026 YTD revenue reconciliation

| Component                                                 | Amount       |
| --------------------------------------------------------- | ------------ |
| Heartland positive settlements                            | $60,832.06   |
| GetHairMD cash receipts                                   | $33,050.00   |
| SportsIQ cash receipt                                     | $8,785.00    |
| Customer refunds and chargebacks, net of reversal         | ($11,842.88) |
| Net customer cash receipts                                | $90,824.18   |
| Adjustment replacing device collections with earned sales | $85,795.00   |
| Preliminary accrual revenue                               | $176,619.18  |

### Lionheart 240 Stimulus cost of goods sold

| Customer / delivery                      | Units | Factory COGS |
| ---------------------------------------- | ----- | ------------ |
| GetHairMD – July delivery                | 10    | $6,400       |
| GetHairMD – five-unit order counted once | 5     | $3,200       |
| SportsIQ – cumulative delivered devices  | 4     | $2,560       |
| Oregon clinic – April delivery           | 1     | $640         |
| Total                                    | 20    | $12,800      |

Factory cost is $640 per device, FOB Amparo, Brazil.

2022 covers September 23–December 31\. FY 2023–2025 covers January–December. The 2026 interim period is not a full year and has not been annualized. Pending means not established on a reconciled, comparable basis; it does not mean zero.

1. The May 28, 2026 annual P&L reports $117,068.22 sales/services and a $45,301.32 net loss. A separate consolidated draft reports $353,969 revenue and $547,302 net loss. Entity scope, consolidation, adjustments and grant classification remain unreconciled; the historical figures above follow the underlying annual P&L, not the investor graphic.
2. 2026 YTD covers January 1–October 23, 2026 and is an unaudited preliminary accrual conversion prepared October 24, 2026, prior to CPA review. Preliminary sales and service revenue of $176,619.18 includes earned device sales to GetHairMD and SportsIQ and provisional eStore revenue (see the revenue reconciliation below); it is not a completed GAAP revenue reconciliation. Other product COGS, inventory, expense cutoffs and remaining accruals are unresolved, so gross profit, total operating expenses and net income are not yet determinable.
3. Historical expense captions follow the source statements; the 2023 and 2024 totals include interest expense. They are not uniformly classified operating expense totals.
4. 2025 other income includes a $250,000 XPRIZE research grant and $3,782.12 miscellaneous income. Grant income is shown separately from product/service sales.
5. 2022 launch-period basis: Figures reflect Lionheart Health, Inc.’s direct bank-account activity from account opening on September 23 through December 31, 2022\. They exclude allocated support from Leonhardt Ventures LLC and Cal-X Stars Business Accelerator, Inc.
6. Factory cost of $640 per Lionheart 240 Stimulus device, FOB Amparo, Brazil, for 20 delivered units (detail below). It excludes freight, insurance, duties and customs handling, which will be allocated to units sold when documented.
7. Non-cash estimate of executive compensation earned January 1–October 23, 2026 at prior management accrual rates. It may be reduced to $0 if conditioned restricted stock is accepted. Payroll taxes, interest and stock compensation remain pending.

The 2026 sales forecast is management’s estimate and is not YTD revenue. Loans, equity proceeds and founder funding are not sales.

Lionheart has engaged a new CFO, Scott Jordan, and a new accountant, Matt Stamer, to review and upgrade the financials, including restricted stock and stock option accounting. They join Jasmin Arredondo, who has been with the company since 2011\. This summary will be updated as that review progresses.

## Annual Reports

* 2025 Annual Report & 2026 Targets  
Oct 12, 2026[View](https://investors.lionheartlongevity.com/docs/lionheart-2025-annual-report.pdf)

## Financial Documents

[All company documents →](https://investors.lionheartlongevity.com/resources/documents)

* Unit Gross MarginsBoard reference, September 23, 2026.[View PDF](https://investors.lionheartlongevity.com/docs/lionheart-unit-gross-margins-2026-09-23.pdf)

Ownership

## Top 20 Shareholders

Based on the company’s underlying workbook schedules, total shares after assumed exercise would be 55,426,724.67.

| Rank | Shareholder                                                  | Shares after exercise | Ownership   |
| ---- | ------------------------------------------------------------ | --------------------- | ----------- |
| 1    | 1\. Leonhardt Ventures LLC                                   | 50,150,000            | 90.2892%\*  |
| 2    | 2\. Dr. Leslie Miller                                        | 1,225,000             | 2.2055%     |
| 3    | 3\. Lynn Hammerschmidt                                       | 633,815               | 1.1411%     |
| 4    | 4\. Scott Hoots                                              | 402,666.67            | 0.7250%     |
| 5    | 5\. Kathleen E. Newton 2015 Irrevocable Trust                | 157,000               | 0.2827%     |
| 6    | 6\. Robert S. & Kathleen J. Brunswick Revocable Family Trust | 157,000               | 0.2827%     |
| 7    | 7\. Joseph S. Mullings 2022 Irrevocable Trust                | 143,750               | 0.2588%\*\* |
| 8    | 8\. Brian Hardy                                              | 122,500               | 0.2205%     |
| 9    | 9\. Brian Lasater                                            | 122,500               | 0.2205%\*   |
| 10   | 10\. Dr. Cristiane Carboni                                   | 122,500               | 0.2205%     |
| 11   | 11\. Dr. Jorge Genovese                                      | 122,500               | 0.2205%     |
| 12   | 12\. Dr. Sanjay Bhojraj                                      | 122,500               | 0.2205%\*   |
| 13   | 13\. Howard Leonhardt                                        | 122,500               | 0.2205%\*   |
| 14   | 14\. Jon Dillon                                              | 122,500               | 0.2205%\*   |
| 15   | 15\. Kelsie Leonhardt                                        | 122,500               | 0.2205%     |
| 16   | 16\. Scott Jordan                                            | 117,000               | 0.2106%     |
| 17   | 17\. James Dorsey                                            | 110,000               | 0.1980%\*\* |
| 18   | 18\. Alan R. and Theresa M. Lampe Living Trust               | 100,000               | 0.1800%\*   |
| 19   | 19\. Mike Parrott                                            | 100,000               | 0.1800%\*   |
| 20   | 20\. Eric and Paulette Jeanotte                              | 82,309                | 0.1482%\*   |

Basis: 37,599,114 existing common shares + 18,407,910.67 listed options/warrants − 580,300 Dave Boyd options/warrants. Holdings are shown separately by registered holder.

\* Subject to increase change with convertible debt note or earned pay conversion.

\*\* Subject to reduction change.

[Management analysisIndustry ComparablesLionheart Health versus seven of its nearest peer companies: IP, clinical studies and team experience.View analysis →](https://investors.lionheartlongevity.com/financials/comparables)

Disclosure

These figures are preliminary internal management information, unaudited and prior to CPA review. They combine historical book records with a separately identified partial accrual conversion for the 2026 interim period and are not a uniform GAAP comparative presentation. They may change materially following reconciliation, consolidation, CPA review or audit.

Source files: 2022 Profit and Loss, direct cash expenses only (revised October 20, 2026); 2024 Financial Statement (official), including 2023 comparison; 2025 Profit & Loss by month (prepared May 28, 2026); 2026 YTD Preliminary Accrual Financials (prepared October 24, 2026); consolidated audit package (September 13 draft, used only to identify conflicts).